Summit Therapeutics Income Statement (2016-2025) | SMMT

1Y3Y5Y7Y10YAll
Download Data
Income Statement Apr2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Apr2018 Jul2018 Oct2018 Jan2019 Mar2019 Jul2019 Oct2019 Dec2019 Mar2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.19M-0.28M0.74M2.14M2.16M6.13M3.46M5.43M50.59M0.88M0.65M0.49M0.15M0.02M0.32M0.22M-3.12M-3.10M-2.45M-0.01M
Operating items
Research & Development -6.86M7.55M-5.10M-5.95M-6.28M8.53M9.77M-16.25M-12.62M-10.64M-12.23M-11.32M-8.94M-12.50M17.05M5.39M15.32M24.81M30.87M30.80M37.72M51.38M51.27M208.02M131.10M
Selling, General & Administrative -2.05M2.67M-2.46M-3.76M-3.04M3.21M2.61M-3.26M-3.61M-6.04M-3.87M-3.08M-5.40M-0.67M5.57M7.58M5.43M11.57M11.52M13.81M20.65M14.54M15.59M360.42M103.11M
Other Operating Expenses 0.000.05M-5.31M0.02M0.03M-0.02M-0.02M5.46M1.13M0.27M0.18M15.01M-0.26M0.20M
Operating Expenses -8.91M10.23M-7.55M-9.70M-9.32M11.74M12.37M-19.51M-21.54M-16.69M-16.10M-14.40M-14.35M-13.17M22.62M21.43M20.76M36.39M42.39M59.62M58.38M65.93M66.85M568.44M234.21M
Operating Income -8.83M-10.21M-6.81M-7.56M-7.17M-5.61M6.84M-9.24M32.64M-12.14M-7.54M-7.96M-9.52M-7.60M-16.94M-20.30M-20.49M-36.21M-58.38M-65.61M
EBIT -8.83M-10.21M-6.81M-7.56M-7.17M-5.61M6.84M-9.24M32.64M-12.14M-7.54M-7.96M-9.52M-7.60M-16.94M-20.30M-20.49M-36.21M-58.38M-65.61M
Non-operating items
Interest & Investment Income 0.00M0.00M0.00M0.00M-0.00M0.00M4.06M-0.00M3.71M0.00M0.00M0.00M0.00M
Other Non Operating Income 0.06M-0.15M-0.18M1.13M0.59M-0.64M0.34M1.88M0.90M-2.55M3.53M
Non Operating Income -4.45M5.47M-0.78M16.10M2.04M2.33M4.58M4.42M3.94M2.73M2.42M
Net income details
EBT -9.10M-10.50M-7.12M-7.83M7.44M-5.89M-16.92M-9.51M36.17M-12.22M-7.60M-8.03M-9.60M-7.66M-16.94M-20.30M-20.49M-36.21M-60.83M-65.62M
Profit After Tax -7.76M-8.99M-5.91M-6.11M-5.94M-4.23M1.14M-8.19M35.51M-10.56M-6.61M-6.95M-8.70M-6.33M-21.39M-19.23M-21.27M-36.57M-43.47M-60.38M-56.25M-61.20M-62.91M-565.71M-231.79M
Income from Continuing Operations -9.10M-10.50M-7.12M-7.83M7.44M-5.89M-16.92M-9.51M36.17M-12.22M-7.60M-8.03M-9.60M-7.66M-16.94M-20.30M-20.49M-36.21M-60.83M-65.62M
Consolidated Net Income -9.10M-10.50M-7.12M-7.83M7.44M-5.89M-16.92M-9.51M36.17M-12.22M-7.60M-8.03M-9.60M-7.66M-16.94M-20.30M-20.49M-36.21M-60.83M-65.62M
Income towards Parent Company -9.10M-10.50M-7.12M-7.83M7.44M-5.89M-16.92M-9.51M36.17M-12.22M-7.60M-8.03M-9.60M-7.66M-16.94M-20.30M-20.49M-36.21M-60.83M-65.62M
Net Income towards Common Stockholders -9.10M-10.50M-7.12M-7.83M7.44M-5.89M-16.92M-9.51M36.17M-12.22M-7.60M-8.03M-9.60M-7.66M-16.94M-20.30M-20.49M-36.21M-60.83M-65.62M
Additional items
EPS (Basic) -0.78-0.86-0.58-0.640.60-0.48-1.37-0.652.46-0.83-0.24-0.25-0.30-0.24-0.10-0.04-0.03-0.01-0.06-0.09-0.08-0.09-0.09-0.76-0.31
EPS (Weighted Average and Diluted) -0.07-0.190.33-0.11-0.34-0.05-0.10-0.04-0.03-0.01-0.06-0.09-0.08-0.09-0.09-0.76-0.31
Shares Outstanding (Weighted Average) 11.67M12.26M12.26M12.26M12.37M12.37M12.37M14.71M14.71M14.71M32.08M32.08M32.08M32.08M32.08M32.08M67.18M82.26M82.92M97.24M97.38M97.71M98.12M98.12M98.12M201.32M697.69M697.69M697.69M700.84M701.70M701.98M724.54M737.45M737.68M742.67M742.85M
Shares Outstanding (Diluted Average) 83.61M86.80M110.16M106.66M22.09M203.49M198.64M42.21M69.52M131.71M208.91M193.34M378.16M697.69M697.74M619.65M701.79M707.90M726.66M718.54M738.08M742.62M743.42M
EBITDA -7.77M-8.96M-5.87M-6.13M5.96M-4.22M1.13M8.18M35.53M-10.55M-6.62M6.96M-8.72M6.31M-21.43M-17.91M-21.15M-36.69M-43.47M-60.34M-56.06M-61.18M-63.19M-565.90M-231.75M
Interest Expenses 0.28M0.29M-0.31M-0.27M0.28M0.28M0.30M0.28M-0.19M-0.08M-0.06M-0.08M-0.08M0.07M3.12M3.10M2.45M0.01M